184 related articles for article (PubMed ID: 24715586)
1. Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma.
Andersson C; Oji Y; Ohlson N; Wang S; Li X; Ottander U; Lundin E; Sugiyama H; Li A
Cancer Med; 2014 Aug; 3(4):909-18. PubMed ID: 24715586
[TBL] [Abstract][Full Text] [Related]
2. Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Kunze CA; Dietel M; Braicu I; Letsch A; Darb-Esfahani S
Gynecol Oncol; 2016 Mar; 140(3):494-502. PubMed ID: 26721227
[TBL] [Abstract][Full Text] [Related]
3. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
[TBL] [Abstract][Full Text] [Related]
4. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
[TBL] [Abstract][Full Text] [Related]
5. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor.
Oji Y; Kitamura Y; Kamino E; Kitano A; Sawabata N; Inoue M; Mori M; Nakatsuka S; Sakaguchi N; Miyazaki K; Nakamura M; Fukuda I; Nakamura J; Tatsumi N; Takakuwa T; Nishida S; Shirakata T; Hosen N; Tsuboi A; Nezu R; Maeda H; Oka Y; Kawase I; Aozasa K; Okumura M; Miyoshi S; Sugiyama H
Int J Cancer; 2009 Jul; 125(2):381-7. PubMed ID: 19384943
[TBL] [Abstract][Full Text] [Related]
6. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
[TBL] [Abstract][Full Text] [Related]
7. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
8. Wilms' tumor 1 antigen immunoreactivity in epithelial ovarian cancer - diagnostic and prognostic value.
Zarychta E; Lepinay K; Szubert S; Jozwicki J; Misiak J; Brozyna AA; Kosinska-Kaczynska K; Lewandowska A; Malicka E; Makarewicz A; Rhone P; Jozwicki W
Folia Histochem Cytobiol; 2020; 58(3):198-207. PubMed ID: 32960974
[TBL] [Abstract][Full Text] [Related]
9. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
Köbel M; Kalloger SE; Boyd N; McKinney S; Mehl E; Palmer C; Leung S; Bowen NJ; Ionescu DN; Rajput A; Prentice LM; Miller D; Santos J; Swenerton K; Gilks CB; Huntsman D
PLoS Med; 2008 Dec; 5(12):e232. PubMed ID: 19053170
[TBL] [Abstract][Full Text] [Related]
10. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers.
Dobrzycka B; Terlikowski SJ; Kinalski M; Kowalczuk O; Niklinska W; Chyczewski L
Ann Oncol; 2011 May; 22(5):1133-1140. PubMed ID: 21098618
[TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients.
Heimes AS; Schmidt M; Jäkel J; Almstedt K; Gebhard S; Weyer-Eiberich V; Elger T; Krajnak S; Brenner W; Hasenburg A; Battista MJ
Arch Gynecol Obstet; 2019 Jan; 299(1):239-246. PubMed ID: 30357498
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
[TBL] [Abstract][Full Text] [Related]
14. The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Santón A; Gonzalez BO; López-Reig R; Hardisson D; Vera-Sempere F; Illueca C; Vieites B; López-Guerrero JA; Palacios J; Poveda A
Am J Surg Pathol; 2020 Feb; 44(2):149-161. PubMed ID: 31498173
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
16. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
17. Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer.
Muallem MZ; Parashkevova A; Almuheimid J; Richter R; Diab Y; Braicu EI; Sehouli J
Anticancer Res; 2017 Jun; 37(6):3157-3161. PubMed ID: 28551658
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
[TBL] [Abstract][Full Text] [Related]
19. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
